Capricor Therapeutics
CAPR
22 hedge funds and large institutions have $3.84M invested in Capricor Therapeutics in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
28% more capital invested
Capital invested by funds: $3.01M → $3.84M (+$836K)
16% more funds holding
Funds holding: 19 → 22 (+3)
0.52% more ownership
Funds ownership: 0.42% → 0.95% (+0.52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
+$2.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$587K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$103K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$60.3K |
| 5 |
Bank of New York Mellon
New York
|
+$59.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$190K |
| 2 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$142K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$78K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$4.87K |
| 5 |
JP Morgan Chase
New York
|
-$4K |
CAPR Hedge Fund Activity: Q4 2017 in Review
22 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2017, worth a combined $3.84M — up 28% from $3.01M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CAPR positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Brown Advisory, opening a new position worth an estimated $2.46M. The largest seller was Jane Street, exiting entirely with an estimated $190K sold.
- 22 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2017, up from 19 in Q3 2017.
- Funds reported $3.84M of Capricor Therapeutics stock for Q4 2017, up 28% quarter-over-quarter.
- 7 funds opened new Capricor Therapeutics positions in Q4 2017 and 4 closed out, a net change of +3 holders.
- The largest Capricor Therapeutics buyer in Q4 2017 was Brown Advisory, an estimated $2.46M added.
- The largest Capricor Therapeutics seller in Q4 2017 was Jane Street, an estimated $190K sold.
Based on aggregated 13F filings for Q4 2017.